U.S. markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.26+0.29 (+1.71%)
At close: 4:00PM EDT
Sign in to post a message.
  • a
    anonymousrex
    $28-$32 million seems to be the "analyst " consensus on Orladeyo sales. Let's see---brand new drug had $10.9 million in sales in it's first PARTIAL quarter on the market. You will have all of the refill Rx's plus at least the sdame amount of new patients filling Rx's for the first time---which should be a higher number than the last quarter since many doctors have probably contacted their patients informing them of the new treatment and moving up their visits. I expect between $35-$40 million in sales. Then you also have to add in the $15 million payment from Torii which was not included in last quarters revenue and that gives you $50-$55 million in revenue. Add in another few million for the 20% quarterly royalty from Torii on their revenue in Japan pushing that total even higher. The market reacts very strongly and positively to revenue increases in the hundreds of percent quarter over quarter, and this is going to continue for a few quarters. WHO still has the cajones to short BCRX leading into numbers like this? TREMENDOUS growth ahead for BCRX----in revenue, profit, and stock price.
  • C
    Crash
    New patent for BCRX SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS

    Abstract
    Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity. ##STR00001##

    Inventors: Kotian; Pravin L.; (Hoover, AL) ; Babu; Yarlagadda S.; (Birmingham, AL) ; Zhang; Weihe; (Vestavia Hills, AL) ; Lu; Peng-Cheng; (Vestavia Hills, AL) ; Wu; Minwan; (Vestavia Hills, AL) ; Lv; Wei; (Hoover, AL) ; Nguyen; Trung Xuan; (Hoover, AL) ; Dang; Zhao; (Vestavia Hills, AL) ; Chintareddy; Venkat R.; (Vestavia Hills, AL) ; Kumar; V. Satish; (Birmingham, AL) ; Raman; Krishnan; (Birmingham, AL)
    Applicant:
    Name City State Country Type

    BioCryst Pharmaceuticals, Inc.
    Durham
    NC
    US
    Family ID: 1000005466441
    Appl. No.: 17/202965
    Bullish
  • a
    anonymousrex
    Highest close today since June 25th. Earnings in just over 2 weeks----and the Bollinger bands are tightening....
  • N
    ND
    Been around since the $3.50 days and still holding strong. Still impressed with one the best small molecule teams around. The best is yet to come!
  • L
    Louis
    You will not see 17.04 today. My theory and hope is 17.35 at closing.
    Bullish
  • C
    Crash
    JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Biocryst Pharmaceuticals on Wednesday, setting a price target of $22, which is approximately 40.94% above the present share price of $15.61.
  • r
    raminder
    This new patent alone could make bcrx a takeover target for big boys .
    Perfect size company with tremendous growth potential if plugged into
    global marketing .exciting days and months ahead
    Bullish
  • a
    anonymousrex
    I hope many of you took the opportunity to add yesterday during the market drop which sucked BCRX down along with nearly everything else. The chart is showing a pretty hard bottom put in on multiple days in the low $15's. Very nice bounce today which I expect to continue leading into earnings. The Bollinger bands are tightening, which generally indicates some kind of break is coming, and my expectation is that it will be to the upside as more publicity gets out, more funds get in, and revenue rises in the hundreds of percent each quarter for a while. We will see what kind of reaction there is when the revenue number goes from $10.9 million into the $50-$60 million range in just a single quarter, but that isn't typically what causes a stock to drop. Still a good add or entry point as the stock is over 10% below it's recent high and only 2 1/2 weeks until earnings.
  • H
    Horkos
    Seeking alpha article estimates of 32.9 million in sales for O beat the average estimate but may still be too conservative. It will be interesting to see the conversion eagerness. Would also love to know what insurance companies have actually agreed to oh.
  • J
    JC
    If you take a moment to view the max time frame on the chart, you can see that anytime this stock reaches $15 or higher, it plunges way lower. Tremendously overvalued.
    Bearish
  • M
    Mike
    Yesterday I said its up a buck today, I’m going to amend that to $1.30
    Expect a couple big buys around 3pm
    Just a hunch
  • E
    EY
    if you monitor closely the past one year behavior of this stock, it extremely resilient . Any significantly drop due to no reason, it bounce back pretty fast then march up further . That is why I like BCRX so much beside it strong forward looking business opportunities . This has become my highest weightage in my portfolio .

    Let enjoy the fruit together for those believed in BCRX and not look at the small gain. It should be in the multiple by next year from current level.
  • a
    anonymousrex
    We now have a tentative time frame for the pivotal 9930 trial. The trial is set to begin enrolling in very shortly and the trial designs have been posted. A total of 138 patients are expected to take part. The primary endpoint is overall increase in hemoglobin----which should be no problem. There are quite a few secondary endpoints. The overall trial is set to run 52 weeks total, so a speedy enrollment will likely mean results near the end of 2022. By then the company will be long in the black and revenue should be in the hundreds of millions given that the expectation this past quarter of a minimum of $50 million with growth compounding quarterly. It's all good and going to get even better. The stock is an absolute bargain here.
  • C
    Crash
    BCX9930 is likely to provide an alternative treatment for PNH patients and potentially offer superior efficacy than existing treatments, including Soliris (eculizumab) and Ultomiris (ravulizumab)
    Bullish
  • L
    Louis
    Xmas is coming early this year. More precisely August 5th
  • R
    Real_Stacey Kronch
    No need to post other than to say this is my all time favorite holding. And it has not even remotely approached the price levels for so much value and potential.
    Have a great day all. 🍻
    Bullish
  • S
    Stanton
    Mom I’m buried. Venmo me. I pawned my helmet but I need spray paint canisters and a hoodie
    Bullish
  • E
    EY
    Ah, you need to review your portfolio and see which are the counter that do not allow you to get multiple by next year, switch it.

    Before , BCRX is my lowest weightage , but I switch other less potential equity or even lost money stock to BCRX . this is how I gradually accumulate once I have set this as my number one target.
  • C
    Crash
    Best in class Factor D part 1 news on data should come early.
    Bullish
  • a
    anonymousrex
    One critical tidbit from the European presentation regarding Orladeyo: "once-daily ORLADEYO® (berotralstat) at the start of the APeX-2 trial had an 80 percent average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Median attack rates also decreased from 2.7 attacks/month at baseline to 0.0 attacks per month in 16 of 17 months through the same period."
    ZERO ATTACKS PER MONTH!!! For the people plagued by HAE this must sound like a MIRACLE! No more injections---no more rushing to the doctor or hospital with an attack. Just a simple pill. From an average of 2.7 attacks per month down to NONE after 16 months-----and an 80 percent reduction prior to that. That means someone having an average of 20 HAE episodes per year would get down to just 4 within a few months of starting the drug. AMAZING-----and the sky is the limit! I am still sticking with my target of $18.5-$20 by earnings release and possibly a double or more from there within the next 12 months.